Breaking News Instant updates and real-time market news.

VCYT

Veracyte

$7.59

0.01 (0.13%)

08:39
10/18/16
10/18
08:39
10/18/16
08:39

Veracyte should be bought at current levels, says Cantor

After Veracyte preannounced higher than expected revenue, Cantor analyst Bryan Brokmeier says that the revenue beat indicates that the company's reimbursement trends are improving. The analyst thinks that the company is well-positioned to continue getting reimbursed for its tests, and he says that the stock's valuation is "compelling." The analyst recommends buying the shares at current levels.

  • 03

    Nov

  • 29

    Nov

VCYT Veracyte
$7.59

0.01 (0.13%)

06/28/16
COWN
06/28/16
NO CHANGE
Target $8
COWN
Outperform
Cowen surprised Anthem still considers Veracyte's Afirma investigational
Cowen analyst Doug Schenkel noted that a new Anthem (ANTM) medical policy on thyroid nodule testing went into effect today, in which the insurer stated that it still considers Veracyte's (VCYT) Afirma GEC test "investigational and not medically necessary". The updated medical policy is a bit of a "surprising disappointment," said Schenkelm, though he added that the new policy "clearly does not consider some newer data." Veracyte's management is still optimistic that Anthem will issue a positive coverage decision, which could still occur in 2016, according to Schenkel, who has an Outperform rating and $8 price target on Veracyte shares.
07/07/16
PIPR
07/07/16
NO CHANGE
PIPR
New FDA recommendation positive for lab companies, says Piper Jaffray
Piper Jaffray analyst William Quirk says that the FDA has issued draft guidance to streamline its approval process for next-generation sequencing, or NGS, germline tests, which could be a substitute for a Premarket Notification or 510k. The analyst believes streamlined regulatory approaches for NGS tests are a positive for labs with NGS laboratory-developed tests such as CareDx (CDNA), Quest Diagnostics (DGX), Genomic Health (GHDX), LabCorp (LH), Myriad Genetics (MYGN), Natera (NTRA), Oxford Immunotec (OXFD), Sequenom (SQNM), Trovagene (TROV), and Veracyte (VCYT).
08/04/16
SPHN
08/04/16
NO CHANGE
Target $9
SPHN
Overweight
Veracyte price target lowered to $9 from $14 at Stephens
Stephens analyst Drew Jones lowered his price target for Veracyte to $9 from $14 on valuation after the company reported Q2 revenue in line with expectations. Looking ahead, the analyst believes the company remains on track with its pulmonology pipeline. Jones reiterates an Overweight rating on the shares.
09/08/16
CANT
09/08/16
NO CHANGE
Target $13
CANT
Buy
Cantor says buy Veracyte following draft local coverage determination
Cantor analyst Bryan Brokmeier recommends that investors buy shares of Veracyte following the announced draft local coverage determination, or LCD, for the company's Percepta Bronchial Genomic Classifier. The analyst says this draft LCD with Noridian Healthcare Solutions represents over 30M covered lives for its Percepta and represents more than 25% of the U.S. market opportunity. Further, Brokmeier believes other Medicare Administrative Contractors will follow Noridian's lead. The analyst reiterates a Buy rating and $13 price target on the shares.

TODAY'S FREE FLY STORIES

DGX

Quest Diagnostics

$110.14

0.44 (0.40%)

, WMT

Wal-Mart

$75.59

0.75 (1.00%)

15:12
06/26/17
06/26
15:12
06/26/17
15:12
Recommendations
Quest Diagnostics, Wal-Mart analyst commentary  »

Raymond James positive on…

DGX

Quest Diagnostics

$110.14

0.44 (0.40%)

WMT

Wal-Mart

$75.59

0.75 (1.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

NOV

National Oilwell

$31.84

0.2 (0.63%)

15:10
06/26/17
06/26
15:10
06/26/17
15:10
Options
Notable call writing in National Oilwell »

Notable call writing in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

VTR

Ventas

$71.94

0.215 (0.30%)

15:07
06/26/17
06/26
15:07
06/26/17
15:07
Conference/Events
Ventas management to meet with RBC Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

MU

Micron

$32.50

0.765 (2.41%)

15:05
06/26/17
06/26
15:05
06/26/17
15:05
Options
Micron call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 29

    Jun

  • 29

    Aug

MAR

Marriott

$104.06

0.17 (0.16%)

15:00
06/26/17
06/26
15:00
06/26/17
15:00
Conference/Events
Marriott management to meet with RBC Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

AAPL

Apple

$146.28

0.65 (0.45%)

, HTZ

Hertz

$10.92

1.38 (14.47%)

14:54
06/26/17
06/26
14:54
06/26/17
14:54
Periodicals
Apple only leasing six cars from Hertz, CNBC says »

After Bloomberg reported…

AAPL

Apple

$146.28

0.65 (0.45%)

HTZ

Hertz

$10.92

1.38 (14.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

NG

NovaGold

$4.50

-0.075 (-1.64%)

14:49
06/26/17
06/26
14:49
06/26/17
14:49
Options
NovaGold options imply 6.4% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

AAPL

Apple

$146.28

0.65 (0.45%)

, HTZ

Hertz

$10.84

1.3002 (13.63%)

14:47
06/26/17
06/26
14:47
06/26/17
14:47
Periodicals
Hertz to manage small self-driving car fleet for Apple, Bloomberg says »

Apple (AAPL) is leasing a…

AAPL

Apple

$146.28

0.65 (0.45%)

HTZ

Hertz

$10.84

1.3002 (13.63%)

GOOG

Alphabet

$965.59

8.5 (0.89%)

GOOGL

Alphabet Class A

$986.09

9.47 (0.97%)

CAR

Avis Budget

$24.24

1.23 (5.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 28

    Jun

  • 28

    Jun

  • 19

    Jul

OTIC

Otonomy

$18.75

1 (5.63%)

14:46
06/26/17
06/26
14:46
06/26/17
14:46
Conference/Events
Otonomy to hold a breakfast meeting »

Chief Scientific Officer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DGX

Quest Diagnostics

$110.05

0.345 (0.31%)

, WMT

Wal-Mart

$75.61

0.77 (1.03%)

14:44
06/26/17
06/26
14:44
06/26/17
14:44
Hot Stocks
Quest Diagnostics, Wal-Mart team up to offer healthcare services »

Quest Diagnostics (DGX)…

DGX

Quest Diagnostics

$110.05

0.345 (0.31%)

WMT

Wal-Mart

$75.61

0.77 (1.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

EBSB

Meridian Bancorp

14:43
06/26/17
06/26
14:43
06/26/17
14:43
Upgrade
Meridian Bancorp rating change  »

Meridian Bancorp upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMD

AMD

$14.17

-0.21 (-1.46%)

, INTC

Intel

$34.19

-0.17 (-0.49%)

14:43
06/26/17
06/26
14:43
06/26/17
14:43
Recommendations
AMD, Intel analyst commentary  »

Goldman reiterates Sell…

AMD

AMD

$14.17

-0.21 (-1.46%)

INTC

Intel

$34.19

-0.17 (-0.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 29

    Aug

KTOV

Kitov Pharmaceuticals

$1.71

-0.01 (-0.58%)

, PRXL

Parexel

$86.80

-0.31 (-0.36%)

14:41
06/26/17
06/26
14:41
06/26/17
14:41
Hot Stocks
Kitov sees formal filing of NDA for KIT-302 by end of Q3 »

Kitov Pharmaceuticals…

KTOV

Kitov Pharmaceuticals

$1.71

-0.01 (-0.58%)

PRXL

Parexel

$86.80

-0.31 (-0.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

RAD

Rite Aid

$3.93

0.8199 (26.36%)

14:40
06/26/17
06/26
14:40
06/26/17
14:40
Options
Heavy trading in RiteAid as shares surge »

Heavy trading in RiteAid…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:40
06/26/17
06/26
14:40
06/26/17
14:40
General news
Treasury Action: yields remain slightly lower »

Treasury Action: yields…

EVLV

EVINE Live

$1.04

-0.03 (-2.80%)

14:39
06/26/17
06/26
14:39
06/26/17
14:39
Conference/Events
EVINE Live management to meet with Craig-Hallum »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 29

    Jun

EVLV

EVINE Live

$1.04

-0.03 (-2.80%)

14:38
06/26/17
06/26
14:38
06/26/17
14:38
Conference/Events
EVINE Live management to meet with B. Riley »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 29

    Jun

HTZ

Hertz

$10.19

0.65 (6.81%)

14:36
06/26/17
06/26
14:36
06/26/17
14:36
Technical Analysis
Technical View: Hertz spikes higher, levels to watch »

The shares were last at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMAG

AMAG Pharmaceuticals

$18.35

0.15 (0.82%)

14:36
06/26/17
06/26
14:36
06/26/17
14:36
Recommendations
AMAG Pharmaceuticals analyst commentary  »

AMAG delay for Makena…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FN

Fabrinet

$45.60

5.58 (13.94%)

14:30
06/26/17
06/26
14:30
06/26/17
14:30
Options
Timely call activity in Fabrinet »

Timely call activity in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 12

    Jul

  • 13

    Jul

  • 29

    Aug

AAPL

Apple

$146.28

0.65 (0.45%)

, HTZ

Hertz

$10.24

0.7 (7.34%)

14:26
06/26/17
06/26
14:26
06/26/17
14:26
Periodicals
Breaking Periodicals news story on Apple, Hertz »

Hertz to manage small…

AAPL

Apple

$146.28

0.65 (0.45%)

HTZ

Hertz

$10.24

0.7 (7.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

GM

General Motors

$34.49

0.29 (0.85%)

14:25
06/26/17
06/26
14:25
06/26/17
14:25
Conference/Events
General Motors to host a conference call »

EVP & CFO Chuck…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 25

    Jul

T

AT&T

$38.15

0.2001 (0.53%)

14:20
06/26/17
06/26
14:20
06/26/17
14:20
Options
Calendar call spread in AT&T rolls short position from July to September »

Calendar call spread in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:19
06/26/17
06/26
14:19
06/26/17
14:19
General news
Averages mixed but internals strong »

The averages remain mixed…

$NSD

NASDAQ Market Internals

14:17
06/26/17
06/26
14:17
06/26/17
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.